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Abstract Background:Apolipoprotein M (ApoM) is bound to high-density lipoprotein (HDL) in plasma,and HDL has anticoagulation effects. However, the association between ApoM and biomarkers of coagulation was unclear.
Therefore,we investigated relationships between ApoM and biomarkers of coagulation.
Methods: Serum samples from 233 Japanese participants including with diabetes mellitus, hypertension,
dyslipidemia, or healthy controls were analyzed. Serum ApoM levels were measured using Enzyme-Linked Immuno-Sorbent Assay(ELISA).
Results:Analysis of all 233 participants showed that ApoM levels were positively correlated with age(r＝0.284,
p＜0.001),total cholesterol (TC;r＝0.477,p＜0.001),HDL-cholesterol (HDL-C;r＝0.234,p＜0.001) and low-
density lipoprotein cholesterol (LDL-C;r＝0.331,p＜0.001). Higher ApoM levels were correlated with shorter activated partial thromboplastin time(APTT;r＝－0.226,p＝0.001)and prothrombin time(PT,％;r＝0.326,p＜
0.001). Separate analysis of the 115 healthy controls showed that ApoM levels were positively correlated with age,
TC,HDL-C and LDL-C,and higher ApoM levels were correlated with shorter PT.
Conclusion:Serum levels of ApoM may influence biomarkers of coagulation.
Introduction
 
Higher levels of blood lipid have been linked to increased coagulation factors, and shorter activated partial thromboplastin time(APTT)and prothrombin time(PT).???Fat intake was shown to be associated with increased levels of coagulation factors.??On the other hand,high-density lipoprotein (HDL)regulates anticoagulation through inactivation of coagulation factors Va and VIIa.?HDL-C is inversely related to levels of prothrombin fragment F1＋2 and D-dimer.?
HDL modulates platelet reactivity, coagulation, and endothelial function.????HDL modulates endothelial function via HDL-associated sphingosine 1-phosphate
(S1P)/S1P specific receptors and via apolipoprotein A
(apoA)/scavenger receptor class B type I (SR-BI).??
Apolipoprotein M (ApoM),which is highly associated with HDL,was recently reported to be a major carrier of S1P in plasma.?? HDL-associated S1P bound to ApoM has a protective effect on the endothelium??,
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lower levels of ApoM may predict VTE recurrence in male patients. Although these reports indicate that HDL-associated ApoM has an antithrombotic effect,
the role of ApoM in coagulation remains unclear. In this study,we investigated the possible role of ApoM in modulating coagulation, and examined whether serum ApoM may influence biomarker of coagulation.
Material and Methods
 
1. Study population The study recruited 233 Japanese participants
(mean age;37.2±15.0). All participants were volun-
tarily enrolled in the study and included participants with diabetes mellitus(n＝12),impaired glucose tole-
rance (n＝7), hypertension (n＝34), or dyslipidemia
(n＝66),and healthy controls (n＝115). Twenty-five participants suffered from diseases more than two.
Healthy controls had no disease or illness,were not taking any medicine,and had no abnormal laboratory test results. They were excluded as healthy controls if they had HDL-cholesterol＜40 mg/dl, triglycerides
(TG)＞150 mg/dl,low density lipoprotein-cholesterol
(LDL-C)＞140 mg/dl,fasting plasma glucose(FPG)＞
110mg/dl, or body mass index (BMI)＞25 kg/m?.
Finally,115 participants were chosen as healthy con-
trols(Fig.1). Characteristics of the entire group of 233 participants (healthy controls and participants with diabetes mellitus, impaired glucose tolerance, hyper-
tension, and dyslipidemia) and the 115 healthy con-
trols are summarized in Table 1A and B,respectively.
This study was approved by the Ethics Committee of Gunma University Graduate School of Medicine.
Informed consent was obtained from all participants.
2. Clinical examination and laboratory investiga-
tions In the morning after a 12-hour fast, anth-
ropometric measurements were performed and blood samples were collected into three polypropylene tubes for serum and plasma analyses. Blood samples were obtained by antecubital venous puncture using 23 G needles while the participant was seated. Serum sam-
ples from all 233 participants were analyzed. Total cholesterol (TC), HDL-C, LDL-C, and TG were measured using a Hitachi LABOSPECT 008(Hitachi,
Tokyo,Japan). PT and APTT were determined using a Sysmex CS-5100 analyzer (Sysmex). PT was de-




Fig.1 Selection of healthy controls. Two hundred thirty-three
 
Japanese participants, including  participants with
 
diabetes mellitus (n＝19), hypertension (n＝34), or
 
dyslipidemia(n＝66),and healthy control subjects(n＝
115)voluntarily enrolled in this study. The 115 healthy
 
controls had no disease or illness,were not taking medi-
cine,had normal laboratory test results for HDL-C (＞40
 
mg/dl),TG (＜150 mg/dl),LDL-C (＜140 mg/dl),FPG
(＜110 mg/dl),and were not obese(BMI＜25 kg/m?).
Table 1A Characteristics of 233 volunteers including healthy controls,diabetes mellitus,dyslipidemia and hypertension.
Characteristics  Total  Male  Female  p
 
Number(n) 233  142  71
 
Age(year) 37.18± 14.99  36.11± 14.77  38.86± 15.27  0.088
 
Height (cm) 165.93± 9.01  171.14± 6.5  157.79± 5.76 ＜0.001?
Weight (kg) 62.39± 13.14  69.07± 10.93  51.96± 8.8 ＜0.001?
BMI (kg/m?) 22.51± 3.66  23.58± 3.55  20.85± 3.19 ＜0.001?
Apolipoprotein M (mg/ml) 22.97± 4.59  22.52± 4.68  23.66± 4.37  0.031?
Total cholesterol (mg/dl) 198.24± 37.51  193.77± 36.1  205.21± 38.8  0.013?
HDL-C (mg/dl) 59.96± 14.1  55.49± 13.3  66.93± 12.43 ＜0.001?
LDL-C (mg/dl) 111.88± 33.73  111.1± 34.22  113.1± 33.1  0.329
 
LDL-C/HDL-C ratio  2.01± 0.87  2.15± 0.89  1.79± 0.79  0.001?
Triglycerides(mg/dl) 103.99± 82.18  115.37± 93.7  86.23± 55.93  0.002?
Non-HDL-C (mg/dl) 138.28± 38.77  138.28± 37.66  138.27± 40.67  0.499
 
Prothrombin time(％) 101.79± 10.83  100.21± 10.8  104.26± 10.47  0.002?
APTT (sec) 32.28± 3.36  31.69± 3.3  33.2± 3.24 ＜0.001?
Fibrinogen (mg/dl) 246.73± 56.9  237.96± 55.73  260.42± 56.29  0.002?
APTT:activated partial thromboplastin time. Value are mean±SD.? Statistical significance(p＜0.05).
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ApoM levels were determined using sandwich Enzyme-
Linked Immuno-Sorbent Assay (ELISA). BMI was calculated as weight (kg)/(height (m)×height (m)).
3.Statistical analysis Data are expressed as means±standard deviation
(SD). Simple regression analysis was used to assess the relationship between serum apoM concentration and the various factors. All probability values are two-
tailed. A value of p＜0.05 was accepted as indicating statistical significance.
Results
 
1. Results for all 233 participants,including healthy participants, and those with diabetes mellitus,
dyslipidemia,and hypertension The physical characteristics and laboratory find-
ings for all 233 participants,including healthy controls and participants with diabetes mellitus,impaired glu-
cose tolerance, dyslipidemia, or hypertension, are shown in Table 1A. Height,weight, BMI, LDL-C/
HDL-C ratio,and TG of male participants were signif-
icantly higher compared with those of female partici-
pants. Conversely, ApoM levels, TC, HDL-C, PT
(％),APTT,and fibrinogen levels of male participants were significantly lower compared with those of female participants. Nine of 66 subjects with dyslipidemia were treated by lipid lowering therapy,6 subjects were treated by statin,2 subjects were treated by ezetimibe and one subject was treated by fibrate. Six subjects treated by statin and one subject treated by ezetimibe showed normal levels of TC, HDL-C, LDL-C and TG,however,other 2 subjects showed higher levels of TG.
Single linear regression analysis of serum ApoM and physical and biochemical parameters among all partic-
ipants, including healthy controls, is shown in Table 2A. Among all participants(male and female),serum ApoM levels were positively correlated with age(r＝
0.284,p＜0.001),but not with height,weight,or BMI.
Serum ApoM levels were also positively correlated with lipid-related parameters TC (r＝0.477,p＜0.001),
HDL-C (r＝0.234,p＜0.001),LDL-C (r＝0.331,p＜
Table 1B Characteristics of 115 healthy controls.
Characteristics  Total  Male  Female  p
 
Number(n) 115  60  55
 
Age(year) 28.43± 8.65  26.48± 6.53  30.56± 10.12  0.006?
Height (cm) 166.25± 9.42  173.44± 5.6  158.42± 5.77 ＜0.001?
Weight (kg) 57.21± 9.64  64.58± 6.37  49.17± 5.07 ＜0.001?
BMI (kg/m?) 20.55± 1.77  21.45± 1.63  19.57± 1.35 ＜0.001?
Apolipoprotein M (μg/ml) 21.92± 4.28  21.13± 4.16  22.78± 4.28  0.02 ?
Total Cholesterol (mg/dl) 185.43± 29.74  180.65± 27.37  190.65± 31.55  0.037?
HDL-C (mg/dl) 66.38± 10.64  62.57± 10  70.55± 9.79 ＜0.001?
LDL-C (mg/dl) 98.37± 24.52  96.98± 23.72  99.89± 25.5  0.265
 
LDL-C/HDL-C ratio  1.52± 0.44  1.59± 0.47  1.43± 0.4  0.026?
Triglycerides(mg/dl) 67.36± 26.28  73.5± 29.65  60.65± 20.23  0.004?
Non-HDL-C (mg/dl) 119.05± 26.71  118.08± 25.68  120.11± 27.99  0.344
 
Prothrombin time(％) 98.94± 10.86  96.63± 10.81  101.45± 10.45  0.008?
APTT (sec) 33.23± 3.28  32.54± 3.22  33.99± 3.19  0.008?
Fibrinogen (mg/dl) 229.65± 46.37  221.17± 47.54  238.91± 43.62  0.02 ?
APTT:activated partial thromboplastin time. Value are mean±SD.? Statistical significance(p＜0.05).
Fig.2 Correlations of serum apolipoprotein M (ApoM)concentration with high density lipoprotein cholesterol
(HDL-C)concentration in all participants and healthy controls. Serum ApoM concentration was positively
 
correlated with HDL-C concentration (A) and in all participants. Serum ApoM concentration was
 
positively correlated with HDL-C concentration (B)in healthy controls.
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0.001), but not with TG. Higher ApoM levels were associated with shorter PT (r＝0.326, p＜0.001) and APTT (r＝－0.226, p＜0.001). Serum ApoM levels were positively correlated with TG only among female participants(Table 2A). Figure 2 showed that serum ApoM concentration was positively correlated with HDL-C concentration (Fig.2A) in all participants.
These results suggest that serum ApoM levels may differ according to gender and that ApoM levels re-
flected and/or influenced coagulation in all partici-
pants, including those with diabetes mellitus,
dyslipidemia,or hypertension,and healthy controls.
Single linear regression analysis of lipid parameters and biomarkers of coagulation among all participants,
including healthy controls, is shown in Table 3A.
Higher TC levels were correlated with higher levels of fibrinogen and shorter APTT and PT. Similar results were found for LDL-C and TG. Higher levels of LDL-C were correlated with higher levels of fi-
brinogen and shorter APTT. Higher TG levels were correlated with higher fibrinogen levels,shorter APTT and PT. Conversely, higher levels of HDL-C were correlated with lower levels of fibrinogen and longer APTT. These results suggest that in all participants,
including those with diabetes mellitus, hypertension,
or dyslipidemia,and healthy participants,TC,LDL-
C,and TG simultaneously influenced coagulation,and that HDL-C inhibited the coagulation cascade.
2.Results for the 115 healthy controls The physical characteristics and laboratory find-
ings for the 115 healthy controls are shown in Table 1B. Height,weight,BMI,LDL-C/HDL-C ratio,and TG of male healthy controls were significantly higher compared with those of female healthy controls.
ApoM,TC,HDL-C,and age of male healthy controls were significantly lower compared with those of female healthy controls. Coagulation markers such as PT,
Table 2A A single liner regression analysis of serum apolipoprotein M and the various factors among 233 volunteers including healthy
 
controls,diabetes mellitus,dyslipidemia and hypertension.
Analyte  
Total  Male  Female
 
r  p  r  p  r  p
 
Age(year) 0.284 ＜0.001? 0.247  0.003? 0.325  0.002?
Height (cm) －0.119  0.069 －0.035  0.681 －0.069  0.516
 
Weight (kg) －0.066  0.318  0.076  0.371 －0.112  0.289
 
BMI (kg/m?) －0.024  0.712  0.088  0.298 －0.103  0.333
 
Total cholesterol (mg/dl) 0.477 ＜0.001? 0.506 ＜0.001? 0.412 ＜0.001?
HDL-C (mg/dl) 0.234 ＜0.001? 0.185  0.028? 0.24  0.022?
LDL-C (mg/dl) 0.331 ＜0.001? 0.36 ＜0.001? 0.279  0.007?
LDL-C/HDL-C ratio  0.107  0.102  0.154  0.067  0.099  0.349
 
Triglycerides(mg/dl) 0.122  0.062  0.111  0.187  0.257  0.014?
Non-HDL-C (mg/dl) 0.377 ＜0.001? 0.419 ＜0.001? 0.319  0.002?
Prothrombin time(％) 0.326 ＜0.001? 0.323 ＜0.001? 0.292  0.005?
APTT (sec) －0.226  0.001? －0.339 ＜0.001? －0.128  0.226
 
Fibrinogen (mg/dl) 0.106  0.106  0.044  0.601  0.153  0.148
 
APTT:activated partial thromboplastin time.? Statistical significance(p＜0.05). Shaded columns:p＜0.05
 
Table 2B A single liner regression analysis of serum apolipoprotein M and the various factors among 115 healthy controls.
Analyte  
Total  Male  Female
 
r  p  r  p  r  p
 
Age(year) 0.277  0.003? －0.016  0.904  0.427  0.001?
Height (cm) －0.141  0.132  0.052  0.693 －0.01  0.942
 
Weight (kg) －0.134  0.153  0.111  0.4 －0.066  0.634
 
BMI (kg/m?) －0.097  0.304  0.089  0.499 －0.097  0.479
 
Total cholesterol (mg/dl) 0.428 ＜0.001? 0.39  0.002? 0.428  0.001?
HDL-C (mg/dl) 0.478 ＜0.001? 0.377  0.003? 0.521 ＜0.001?
LDL-C (mg/dl) 0.249  0.007? 0.256  0.048? 0.229  0.093
 
LDL-C/HDL-C ratio －0.024  0.8  0.036  0.786 －0.019  0.889
 
Triglycerides(mg/dl) 0.074  0.435  0.099  0.452  0.177  0.196
 
Non-HDL-C (mg/dl) 0.286  0.002? 0.269  0.038? 0.3  0.026?
Prothrombin time(％) 0.22  0.018? 0.107  0.414  0.27  0.046?
APTT (sec) －0.145  0.122 －0.344  0.007? －0.039  0.775
 
Fibrinogen (mg/dl) 0.101  0.282 －0.019  0.888  0.166  0.227
 
APTT:activated partial thromboplastin time.? Statistical significance(p＜0.05). Shaded columns:p＜0.05
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ApoM correlates coagulation
 APTT,and fibrinogen levels of male healthy controls were significantly lower compared with those of female healthy controls.
Single linear regression analysis of ApoM and physical and biochemical parameters among the 115 healthy controls is shown in Table 2B. Serum ApoM levels were positively correlated with TC, HDL-C,
LDL-C,and non-HDL-C. Higher ApoM levels were correlated with shorter PT. For male healthy controls only,higher ApoM levels were correlated with shorter APTT. For female healthy controls only,ApoM levels positively correlated with age,and higher ApoM levels correlated with shorter PT. These results suggest that serum ApoM levels reflected and/or influenced the activity of coagulation in healthy controls.
Single linear regression analysis of lipid parameters and biomarkers of coagulation among the 115 healthy controls is shown in Table 3B. No association was found between TC and biomarkers of coagulation.
Higher values of LDL-C were correlated with shorter APTT. Higher TG levels were correlated with shorter APTT. Figure 2 showed that serum ApoM concentra-
tion was positively correlated with HDL-C concentra-
tion (Fig.2B)in healthy controls.
Discussion
 
This study demonstrated that serum ApoM levels were positively related to biomarkers for coagulation in a group of Japanese subjects including patients with diabetes mellitus, hypertension, or dyslipidemia, and healthy controls. These findings were unexpected results. In plasma, ApoM is mainly bound to HDL.???????HDL regulates anticoagulation through inactivation of coagulation factors Va and VIIa.?
HDL-C is inversely related to levels of prothrombin fragment F1＋2 and D-dimer.?Expectedly, the posi-
tive correlation between ApoM levels and HDL-C levels identified in line with previous findings,???????
and HDL-C levels were related to coagulation,higher levels of HDL-C correlated with lower fibrinogen
 
levels and longer APTT. These findings suggest that HDL-C influenced anticoagulation activity. However,
higher serum ApoM levels were correlated with shorter values of PT and APTT. These results could be partially explained by the close correlation serum ApoM levels and li d parameters. Previous reports demonstrated that close correlations between ApoM levels and lipid parameters.????? In this study we confirmed that serum ApoM levels were positively correlated with HDL-C,TC and LDL-C in line with previous reports.?????When all 233 participants were included in the analysis,TC and LDL-C levels were positively correlated with fibrinogen levels,and were correlated with shorter APTT, and higher TC levels were correlated with shorter PT. These results agree with those reported in previous studies. Higher levels of blood lipid have been linked to increased coagula-
tion factors,and shorter PT and APTT.???Fat intake was shown to be associated with increased levels of coagulation factors.??These previous findings suggest that higher levels of blood lipid are linked to increased coagulation activity. Statin treatment decreases blood lipid levels and hypercoagulability.?????On the other hand,Kappelle et al reported that plasma ApoM was lowered by statin treatment.??Statin-induced decrease in ApoM and a positive correlation between ApoM and LDL-C observed in their study were partly ex-
plained by the hypothesis that high plasma ApoM was linked with slow turnover of plasma LDL receptor,????
and that plasma clearance of ApoM was influenced by LDL receptor-mediated clearance of apoB-containing particles.????As well as serum TC and LDL-C levels,
higher serum ApoM levels were correlated with shorter PT and APTT when all 233 participants were included in the analysis. In the healthy controls,ApoM levels were correlated with shorter PT. Higher ApoM levels were correlated with shorter APTT in male partici-
pants, but not in female participants. These results suggest that ApoM levels influenced coagulation in participants with metabolic disorders and/or hyperten-
sion and in healthy controls, and that influence of
 
Table 3A A single liner regression analysis of lipid parameters and biomarkers of coagulation among 233 volunteers including
 
healthy controls,diabetes mellitus,dyslipidemia and hypertension.
Analyte  
TC  HDL-C  LDL-C  Triglycerides
 
r  p  r  p  r  p  r  p
 
Prothrombin time(％) 0.19  0.004? -0.003  0.962  0.115  0.08  0.262 ＜0.001?
APTT (sec) －0.226  0.001? 0.166  0.011? －0.23 ＜0.001? －0.305 ＜0.001?
Fibrinogen (mg/dl) 0.287 ＜0.001? －0.151  0.021? 0.285 ＜0.001? 0.156  0.017?
APTT:activated partial thromboplastin time ?Statistical significance(p＜0.05). Shaded columns:p＜0.05
 
Table 3B A single liner regression analysis of lipid parameters and biomarkers of coagulation among 115 healtyhy controls.
Analyte  
TC  HDL-C  LDL-C  Triglycerides
 
r  p  r  p  r  p  r  p
 
Prothrombin time(％) 0.111  0.237  0.154  0.1  0.047  0.616  0.126  0.181
 
APTT (sec) －0.182  0.052  0.074  0.432 －0.232  0.013? －0.232  0.012?
Fibrinogen (mg/dl) 0.104  0.269  0.019  0.844  0.089  0.342  0.053  0.574
 
APTT:activated partial thromboplastin time ?Statistical significance(p＜0.05). Shaded columns:p＜0.05
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ApoM in coagulation cascade may differ according to gender. Serum levels of ApoM,TC,LDL-C,and TG were positively related to biomarkers of coagulation,
whereas HDL-C was inversely related to coagulation.
These previous reports and the present results suggest that modulation of ApoM is a potential therapeutic target for thrombogenic diseases.
In conclusion, serum ApoM levels were correlated with biomarkers of coagulation. Further study is needed to clarify the physiological role of ApoM in coagulation.
Limitations This study was a cross-sectional study with a relatively small number participants performed in a single unit. A prospective study including larger participants is necessary to confirm the physiological role of ApoM in coagulation.
Disclosure Statement There was no conflict of interest that has affected the results of this study. The institutional ethics com-
mittee approved this study.
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